Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

This study has been terminated.
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: July 21, 2009
Last updated: September 20, 2013
Last verified: September 2013